Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 5/20 | 0.48 |
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649199 | 0.85 | ACHE (0.59) | ADORA2AADORA1BTKAURKAAURKB | |
| SCHEMBL13329661 | 0.85 | ACHE (0.59) | ADORA2AADORA1BTKAURKAAURKB | |
| SCHEMBL13329702 | 0.82 | ATR (0.47) | AURKAAURKBPDPK1TGFBR1ACHE | |
| SCHEMBL2230496 | 0.81 | KDM4E (0.57) | ADORA2AADORA1AURKAAURKBPDPK1 | |
| SCHEMBL13329688 | 0.81 | ADORA2A (0.53) | ADORA2AADORA1BTKAURKAAURKB | |
| SCHEMBL2200855 | 0.81 | ADORA2A (0.53) | ADORA2AADORA1BTKAURKAAURKB | |
| SCHEMBL13329692 | 0.80 | MKNK1 (0.47) | ADORA2AADORA1BTKAURKAAURKB | |
| SCHEMBL13360798 | 0.80 | ADORA1 (0.48) | ADORA2AADORA1BTKAURKAAURKB | |
| SCHEMBL13329663 | 0.79 | ACHE (0.52) | ADORA2AADORA1BTKAURKAAURKB | |
| SCHEMBL6116586 | 0.79 | BTK (0.61) | BTKACHEMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | ADORA2A 583/4885ADORA1 377/4885BTK 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.